Skip to main content

Health Stocks in Motion

The FDA approves a larger version of CryoLIfe's disposable surgical adhesive syringe.

Shares of



were among the best-performing health-related stocks Thursday, jumping 33% after the developer of cancer treatments said its FavId product received fast-track status from the Food and Drug Administration.

The treatment is used to combat B-cell follicular non-Hodgkin's lyphoma. FavId is currently being evaluated in a phase III clinical trial. "This decision by the FDA has the potential to save us valuable time in the regulatory approval process, and also serves as an important acknowledgement of the potential for FavId in the treatment of B-cell follicular NHL," the company said. Shares were trading up $1.33 to $5.37.


(CRY) - Get CryoLife, Inc. Report

surged 20% after the biosurgical device company said the FDA approved its new 10-milliliter disposable syringe for BioGlue surgical adhesive. The BioGlue syringe is already available in the U.S. in 2-milliliter and 5-milliliter volumes. The 10-milliliter syringe, which is already being used in Europe, will be introduced into the U.S. market late in the first quarter, the company said. "The 10ml BioGlue Syringe provides surgeons with an effective adhesive in an easy-to-use, self-contained, disposable syringe, ideally suited for complex cardiovascular surgery procedures," CryoLife said in a statement. Shares were trading up 78 cents to $4.60.

Shares of

Rockwell Medical Technologies

(RMTI) - Get Rockwell Medical, Inc. Report

rose 5% after the dialysis products maker received a $13 million purchase order for dialysis concentrate and supplies. The order is for dialysis business in Latin America. Rockwell said it anticipates fulfilling the entire order during 2006. "We anticipate that this order will have a favorable impact on both our sales and earnings during 2006," the company said. Shares were trading up 21 cents to $4.63.

Schiff Nutrition


fell 3% after the maker of nutritional supplements posted a big decline in second-quarter earnings and sales. The company, which was previously known as Weider Nutrition, earned $1.5 million, or 6 cents a share, on sales of $35.5 million. During the year-ago period the company earned $3.5 million, or 13 cents a share, on sales of $44.3 million. The sales decline, which was expected, was primarily due to the discontinuance of a private-label business, the company said. Shares were trading down 14 cents to $5.10.

Other health care volume movers included

TheStreet Recommends



, up 29 cents to $16.10;


(PFE) - Get Pfizer Inc. Report

, down 18 cents to $24.57;



, up $2.05 to $22.35;



, down 4 cents to $70.40;

Johnson & Johnson

(JNJ) - Get Johnson & Johnson Report

, down 45 cents to $62.05;

Boston Scientific

(BSX) - Get Boston Scientific Corporation Report

, down 38 cents to $25.03;

Bristol-Myers Squibb

(BMY) - Get Bristol-Myers Squibb Company Report

, down 11 cents to $22.40;


(MRK) - Get Merck & Co., Inc. Report

, down 4 cents to $33.42;



, down 24 cents to $20.15;


(AMGN) - Get Amgen Inc. Report

, down 85 cents to $76.96; and

UnitedHealth Group

(UNH) - Get UnitedHealth Group Incorporated Report

, up 64 cents to $62.49.